Dupilumab ( Dupixent – Sanofi/Regeneron), a subcutaneously injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved for several indications, including treatment of chronic rhinosinusitis…
Med Lett Drugs Ther. 2026 Jun 22; 68(1757):102-3 doi:10.58347/tml.2026.1757e
Dupilumab ( Dupixent – Sanofi/Regeneron), a subcutaneously injected interleukin (IL)-4 receptor alpha antagonist that is FDA-approved for several indications, including treatment of chronic rhinosinusitis with nasal polyps, has now been approved for treatment of allergic fungal rhinosinusitis (AFRS) in patients ≥6 years old who previously had sinonasal surgery. It is the first drug to be approved in the US for this indication.
The FDA has approved remibrutinib ( Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H 1…
Med Lett Drugs Ther. 2026 Jan 5; 68(1745):3-6 doi:10.58347/tml.2026.1745b
The FDA has approved remibrutinib ( Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H 1 -antihistamine treatment. Remibrutinib is the first oral drug to be approved in the US for this indication.
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair , has been approved by the FDA for same indications as Xolair (see Table 1).…
Med Lett Drugs Ther. 2025 Jun 9; 67(1730):95-6 doi:10.58347/tml.2025.1730f
Omlyclo (omalizumab-igec; Celltrion), a biosimilar product interchangeable with the recombinant anti-IgE monoclonal antibody Xolair , has been approved by the FDA for same indications as Xolair (see Table 1). Omlyclo is the first Xolair biosimilar to be approved in the US.